TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05099406

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session.
Study: NCT05023889

Intervention type: DRUG
Group type: OTHER
Intervention: patisiran
Description: Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days).
Study: NCT05586087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (\>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
Study: NCT06523946

Intervention type: BEHAVIORAL
Intervention: Diabetes Prevention Program (DPP) (shortened)
Description: The investigators will adapt the protocol of the 'Ohana project. The 'Ohana protocol was developed based on CDC's Diabetes Prevention Program (DPP) curriculum and designed to fit PcI's cultural background. It includes a 8-lesson curriculum delivered in 8 weeks (shortened from the original 16-lesson, 24-week core curriculum of DPP while retaining all original foci and behavior change strategies). Specifically, the first four lessons, delivered every week, focus on getting the participants started on increasing PA and improving diet (e.g., introduction; getting started on PA and diet; utilizing goal setting; making the process fun). The second four classes will be taught every other week and will focus on how to handle various challenges involved in maintaining healthy lifestyle behaviors. The investigators will deliver the curriculum in group settings of 15 people in a separate room in the National Tongan American Society.
Study: NCT05442892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training programme
Description: The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
Study: NCT06608927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT05179395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brasthesis
Description: Brasthesis is a harness that is integrated with an off the shelf sports bra
Study: NCT05698212

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MetriDx
Description: Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MetriDx
Description: Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MetriDx
Description: Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
Study: NCT06190015

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Advanced platelet rich fibrin (APRF) clots
Description: 15 minutes before surgery, phlebotomy will be performed and two vacutainers containing 10ml of blood will be placed in the centrifuge for 8 min and 200g. Acquired APRF clots will be placed in the extraction alveolus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel matrix derivative (EMD) group
Description: After third molar removal, Pref Gel (EDTA) will be placed on the root surface for 2 min and then removed. Emdogain (EMD) will be placed on the collagen sponge (Botiss, Collacone) and then applied in the wound so that the side of the sponge which is covered with Emdogain is in contact with the root surface.
Study: NCT05835557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR-ST
Description: Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Blood flow restriction will be applied for 2 mins during the passive rest at 80% of limb occlusion pressure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ST
Description: Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Cycling will be conducted in an environmental chamber and participants informed that the altitude is set to 2500m - actual altitude will be sea level.
Study: NCT06319287

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEP (Purified Exosome Product) / TISSEEL
Description: PEP Drug Product is a lyophilized powder contained within a 10R glass vial. PEP Drug Product is a lyophilized powder derived from apheresed platelets in plasma. The powder cake weighs approximately 75 mg per vial. This protocol will evaluate 2 vials of PEP Drug Product delivered in 10 mL TISSEEL fibrin sealant (15mg/mL PEP-TISSEEL) for 12 weeks.~TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: PEP (Purified Exosome Product) / TISSEEL
Description: PEP Drug Product is a lyophilized powder contained within a 10R glass vial. PEP Drug Product is a lyophilized powder derived from apheresed platelets in plasma. The powder cake weighs approximately 75 mg per vial. This protocol will evaluate 2 vials of PEP Drug Product delivered in 10 mL TISSEEL fibrin sealant (15mg/mL PEP-TISSEEL) for 12 weeks.~TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies
Study: NCT05377671

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IRM multimodale a ultra-haute camp
Description: The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IRM multimodale a ultra-haute camp
Description: The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
Study: NCT06433011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bashir™ Endovascular Catheter
Description: The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-tPA
Description: Pulse spray and infusion
Study: NCT06107673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: AI: Take according to the instructions provided.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Hydrochloride Injection
Description: Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide injection
Description: Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Study: NCT05337748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lexie Self Test and Fit Group
Description: The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lexie Professional Test and Fit Group
Description: The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
Study: NCT05432206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Sativa Oil
Description: Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Sativa Oil
Description: Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hemp virgin seed oil
Study: NCT06608927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered as specified in the treatment arm
Study: NCT04692155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
Study: NCT04602754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BERLIM 25/20 ASSOCIATION
Description: Berlim 25/20 association coated tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPAGLIFLOZIN PLACEBO
Description: Empagliflozin placebo coated tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROSUVASTATIN CALCIUM PLACEBO
Description: Rosuvastatin calcium placebo coated tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMPAGLIFLOZIN
Description: Empagliflozin 25 mg coated tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROSUVASTATIN CALCIUM
Description: Rosuvastatin 20 mg coated tablet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BERLIM 25/20 ASSOCIATION PLACEBO
Description: Berlim 25/20 association placebo coated tablet.
Study: NCT05471596

Intervention type: DEVICE
Intervention: NeuWave Microwave Ablation System
Description: The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
Study: NCT06608927

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered as specified in the treatment arm
Study: NCT04902872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
Study: NCT06585982

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: RILLUS is a synbiotic produced by Kalbe Farma

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo produced by Kalbe Farma
Study: NCT06589297

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Modified Rankin scale
Description: Acute stroke patients will undergo modified rankin scale
Study: NCT06601465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: Tablet - 2.5 mg, 5 mg, 10 mg
Study: NCT06589778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: SHR-A2102: injection, 80mg/ bottle, intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebelimab (SHR-1316)
Description: Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip
Study: NCT05786040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study: NCT06666504

Intervention type: OTHER
Intervention: Combined Retrospective and Prospective Data Analysis
Description: Collection of both retrospective and prospective data all ready available for participant
Study: NCT06667700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Study: NCT06609473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHEF Intervention Program
Description: Poverty-targeted intervention utilizing direct resource provision of healthy meal kits and groceries, as well as assisted referral and enrollment in government nutrition assistance benefits, SNAP (Supplement Nutrition Assistance Program) and/or WIC (Woman, Infants, and Children Program). Meal kits will be delivered by a commercial meal kit vendor. Grocery gift cards will be delivered via email, mail, or in-person. Kitchen equipment will be delivered to caregiver residence.
Study: NCT06667011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: learning conversation between trainee and teacher lasting 5 to 10 minutes at the end of each working day
Study: NCT06660173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maridebart Cafraglutide
Description: Solution for subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection.
Study: NCT06481995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrogammin
Description: Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
Study: NCT06654193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic HB-adMSCs
Description: Allogeneic HB-adMSCs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile Saline Solution
Study: NCT05512039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox 50 Unit Injection
Description: Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
Study: NCT05210946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.